We evaluated deferasirox pharmacokinetic according to SNPs in genes involved in its metabolism and elimination. Moreover, we defined a plasma area under the curve cut-off value predicting therapy response.

Role of pharmacogenetics on deferasirox AUC and efficacy

CUSATO, JESSICA;ALLEGRA, SARAH;DE FRANCIA, SILVIA;MASSANO, DAVIDE;PIGA, Antonio Giulio;D'AVOLIO, ANTONIO
Last
2016

Abstract

We evaluated deferasirox pharmacokinetic according to SNPs in genes involved in its metabolism and elimination. Moreover, we defined a plasma area under the curve cut-off value predicting therapy response.
17
6
561
572
ABCG2; SNPs; UGT1A1; UGT1A3; iron overload; pharmacokinetics
Cusato, Jessica; Allegra, Sarah; DE FRANCIA, Silvia; Massano, Davide; Piga, Antonio Giulio; D'Avolio, Antonio
File in questo prodotto:
File Dimensione Formato  
Role of pharmacogenetics on deferasirox AUC and efficacy.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1618840
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact